How to Help Your Patients Save Money on Procainamide: A Provider's Guide to Savings Programs

Medication cost is one of the most common reasons patients skip doses or abandon prescribed therapies—even life-critical ones like antiarrhythmics. Procainamide presents a unique cost challenge: it's an older generic drug with no manufacturer patient assistance program, its oral formulations have been discontinued (making compounding the only oral option), and insurance coverage for compounded formulations is inconsistent. This guide gives providers practical strategies to help patients manage procainamide costs and maintain access to treatment.

Understanding the Cost Landscape for Procainamide

Procainamide costs vary significantly by formulation and setting:

Inpatient/hospital use: Covered under hospital billing (Medicare Part A for inpatient, DRG-based payment). Patient cost-sharing depends on their insurance plan's deductible and coinsurance. Typically not a separate out-of-pocket expense.

Outpatient IV (physician office or infusion center): Billed under Medicare Part B using J-code J2690 (up to 1 g of procainamide injection). Patient owes 20% of the Medicare-approved amount after the Part B deductible is met; supplemental insurance typically covers the remaining 20%.

Retail pharmacy (injectable): Cash price approximately $364.80 for 50 mL (100 mg/mL). Most commercial insurance covers generic injectables; patient cost varies by plan tier.

Compounded oral procainamide: Widely variable—typically $50–$200+ per month depending on dose and pharmacy. Coverage is inconsistent and often requires prior authorization.

Strategy 1: Document Thoroughly for Prior Authorization

For patients seeking insurance coverage of compounded oral procainamide, strong prior authorization documentation is essential. The key argument is simple: the commercial oral formulation is no longer available, making compounding the only option for oral therapy.

Your prior authorization documentation should include:

Statement that commercial oral procainamide (Pronestyl, Procanbid) has been permanently discontinued from the US market

Specific arrhythmia diagnosis (ICD-10 code) and why oral procainamide is appropriate

Documentation of why alternative antiarrhythmic agents are not appropriate (adverse effects, contraindications, failure of alternatives)

Letter of medical necessity if the plan requires it

Strategy 2: Use GoodRx and Prescription Discount Programs

For patients filling procainamide injection at a retail pharmacy, GoodRx and other discount programs (SingleCare, WellRx, RxSaver) may reduce the cash price below the retail list price. These programs are free for patients to use.

Note that discount program pricing cannot be combined with insurance at the point of sale. In some cases, the GoodRx price may actually be lower than a patient's commercial insurance copay—particularly for older generic drugs where insurer markups exist.

Strategy 3: Direct Patients to Financial Assistance Resources

Since there is no manufacturer-sponsored patient assistance program for procainamide, guide uninsured or underinsured patients to these general resources:

NeedyMeds.org: Searchable database of disease foundations, state programs, and other assistance for cardiac medications. A social worker or your office staff can help patients navigate this resource.

RxAssist.org: Another searchable database of pharmaceutical assistance programs

Hospital social work referral: Most hospitals have social workers who specialize in connecting patients with medication assistance resources. A warm handoff to a hospital social worker before discharge is one of the most effective steps you can take.

State pharmaceutical assistance programs: Some states have programs for cardiac medications; NeedyMeds lists state-specific options.

39,049+ patients found their medications in stock

39K+

Find Procainamide In Stock Today →

Strategy 4: Evaluate the Case for Switching to a Commercially Available Alternative

Sometimes the most cost-effective decision for long-term oral maintenance is to transition from procainamide to a commercially available alternative with better formulary status. Potential alternatives for long-term outpatient management include:

Sotalol (generic): Widely available orally, often Tier 1-2 on formularies, appropriate for VT and AF rhythm control in many patients

Flecainide (generic): Available orally, Tier 1-2, appropriate for SVT and AF in patients without structural heart disease

Amiodarone (generic): Very low cost ($4–$20/month at generic prices), Tier 1 on most formularies, broadly effective but requires long-term organ toxicity monitoring

When cost barriers to compounded procainamide are significant, reassess whether an alternative antiarrhythmic with full commercial availability and favorable formulary status is clinically appropriate for your patient.

Strategy 5: Help Patients Find Pharmacies With Procainamide in Stock

Even before cost can be addressed, patients must be able to find a pharmacy that stocks procainamide. medfinder for providers calls pharmacies near the patient and identifies which ones can fill the prescription—reducing the coordination burden on your staff. Recommend medfinder to your patients as part of discharge planning. See also our guide on helping patients find procainamide in stock for a full overview of pharmacy access strategies.